Leiden, The Netherlands, April 5, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it had received a European Commission-funded grant toward the development of a pandemic influenza vaccine. The EUR 1.7 million grant, which was awarded to a consortium of nine leading universities and companies working in the field of influenza research, will finance pre-clinical and clinical testing of H5N1 vaccines.
